Mr. Frohlich, formerly Chief Operating Officer of Chinook Therapeutics, brings 20+ years of leadership experience; Dr. Kocinsky offers deep expertise in developing therapies for autoimmune and kidney diseases Board of Directors, comprised of industry veterans in science, business, and strategy, will support the company's growth Expanded financing to accelerate clinical development of Jade's novel therapies targeting autoimmune diseases with significant unmet need VANCOUVER, BC and SAN FRANCISCO , Oct.
24, 2024 /PRNewswire/ -- Jade Biosciences, Inc . ("Jade"), a biotechnology company dedicated to developing best-in-class therapies for patients living with autoimmune diseases, today announced the appointment of Tom Frohlich as Chief Executive Officer (CEO) and Hetal Kocinsky , M.D.
, as Chief Medical Officer (CMO). The company also introduced its newly formed Board of Directors, marking a significant step in the company's growth trajectory. Jade has extended its financing, bringing the total raised to $95 million .
The financing round adds Frazier Life Sciences and Versant Ventures to an investor syndicate that includes Fairmount, Venrock Healthcare Capital Partners, Deep Track Capital, Driehaus Capital Management, Franklin Templeton , RTW Investments, and Braidwell LP. Strategic Appointments to Lead Jade's Next Growth Phase Tom Frohlich , Chief Executive Officer Mr. Frohlich, a biotech and pharma industry veteran, brings over 20 years of experience in company building, business.
